Contributions
Abstract: EP1502
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 17 Environmental factors
Objective: Vitamin D(VitD) is known to influence immune system function and multiple sclerosis(MS) susceptibility. Modulation of serum cholesterol (Chol) level has been shown to impact on brain atrophy in MS. This study wanted to investigate correlation between VitD and Chol in MS and their association with MS activity and disability progression(DP).
Methods: We reviewed medical records, laboratory data and MRI of subjects newly diagnosed with MS at our specialist center between January2014 and February2017.
We analyzed association between hypovitaminosis D(HypoD) and hypercholesterolemia(HyprCh) with MRI activity (MRIa) when blood sampling and imaging acquisition were less than 120 days(d) apart, and between HypoD or HyprCh less than 120d apart from 1stclinic assessment with occurrence of relapses, MRIa and DP at follow up (mean 492d,range0-2260d).
Finally, we evaluated correlation between VitD and Chol measured in the same sample at all time-points.
We defined HypoD as VitD< 30nmol/L, HyprCh as Chol>5mmol/L, DP as increase of EDSS≥1point after up to 2years and MRIa as presence of T1 gad-enhancement and/or new T2lesions.
Results: 72 patients were included (71% female, mean age 44±14years): 30% were receiving disease modify treatment, 15% statins and 70% VitD supplements (VitDs).
Baseline MRI was performed ≈ 120d before 1st clinic attendance (Median -123d, -2937d-239d); 2nd MRI was performed a median of 364d (41d-2652d) after 1st MRI; 3rdMRI was done a median of 392d (50d-1344d) after 2nd MRI.
Baseline HypoD significantly associate with occurrence of relapses during follow up (χ²,p< 0,05). HypoD does not associate significantly with MRIa at any time-point nor with DP at 2 years; a trend was observed for association between HypoD and new T2lesions in 2ndMRI( χ²,p=0,08). MS patients who had 3rdMRI had normal VitD (69% on VitDs).
HyprCh at baseline and follow up did not associate with MRIa, occurrence of relapses or DP at any time point; a trend was observed for association of HyprCh and new T2lesions in 3rdMRI(χ²,p=0,06).
Serum VitD inversely correlate with Chol (Pearson´s r-0.22,p< 0.01).
Conclusion: HypoD impacts on early MS clinical activity and VitD and Chol serum levels are inversely correlated. This evidence support the need for further studies looking at the effect of VitD and Chol on MS pathophysiology and clinical course.
Disclosure:
Dr Josefa Pérez Lucas: nothing to disclosure.
Mrs Sarah Fuller has nothing to disclose.
Dr Chaudhuri has received speaker honoraria from Biogen Idec, Genzyme and Novartis.
Dr Mattoscio has received speaker honoraria form Novartis and Merk Serono and travel support from Biogen Idec, Novartis, Genzyme and Teva.
Abstract: EP1502
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 17 Environmental factors
Objective: Vitamin D(VitD) is known to influence immune system function and multiple sclerosis(MS) susceptibility. Modulation of serum cholesterol (Chol) level has been shown to impact on brain atrophy in MS. This study wanted to investigate correlation between VitD and Chol in MS and their association with MS activity and disability progression(DP).
Methods: We reviewed medical records, laboratory data and MRI of subjects newly diagnosed with MS at our specialist center between January2014 and February2017.
We analyzed association between hypovitaminosis D(HypoD) and hypercholesterolemia(HyprCh) with MRI activity (MRIa) when blood sampling and imaging acquisition were less than 120 days(d) apart, and between HypoD or HyprCh less than 120d apart from 1stclinic assessment with occurrence of relapses, MRIa and DP at follow up (mean 492d,range0-2260d).
Finally, we evaluated correlation between VitD and Chol measured in the same sample at all time-points.
We defined HypoD as VitD< 30nmol/L, HyprCh as Chol>5mmol/L, DP as increase of EDSS≥1point after up to 2years and MRIa as presence of T1 gad-enhancement and/or new T2lesions.
Results: 72 patients were included (71% female, mean age 44±14years): 30% were receiving disease modify treatment, 15% statins and 70% VitD supplements (VitDs).
Baseline MRI was performed ≈ 120d before 1st clinic attendance (Median -123d, -2937d-239d); 2nd MRI was performed a median of 364d (41d-2652d) after 1st MRI; 3rdMRI was done a median of 392d (50d-1344d) after 2nd MRI.
Baseline HypoD significantly associate with occurrence of relapses during follow up (χ²,p< 0,05). HypoD does not associate significantly with MRIa at any time-point nor with DP at 2 years; a trend was observed for association between HypoD and new T2lesions in 2ndMRI( χ²,p=0,08). MS patients who had 3rdMRI had normal VitD (69% on VitDs).
HyprCh at baseline and follow up did not associate with MRIa, occurrence of relapses or DP at any time point; a trend was observed for association of HyprCh and new T2lesions in 3rdMRI(χ²,p=0,06).
Serum VitD inversely correlate with Chol (Pearson´s r-0.22,p< 0.01).
Conclusion: HypoD impacts on early MS clinical activity and VitD and Chol serum levels are inversely correlated. This evidence support the need for further studies looking at the effect of VitD and Chol on MS pathophysiology and clinical course.
Disclosure:
Dr Josefa Pérez Lucas: nothing to disclosure.
Mrs Sarah Fuller has nothing to disclose.
Dr Chaudhuri has received speaker honoraria from Biogen Idec, Genzyme and Novartis.
Dr Mattoscio has received speaker honoraria form Novartis and Merk Serono and travel support from Biogen Idec, Novartis, Genzyme and Teva.